<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02898805</url>
  </required_header>
  <id_info>
    <org_study_id>AKP_3</org_study_id>
    <nct_id>NCT02898805</nct_id>
  </id_info>
  <brief_title>Effects of LopiGLIK® on Cardiovascular Risk</brief_title>
  <acronym>LopiWEB</acronym>
  <official_title>Effects of a New Combination of Nutraceutics (LopiGLIK®) on Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to compare the effects of two combination of nutraceuticals: Armolipid&#xD;
      Plus® and LopiGLIK® (Akademy Pharma), a new supplement that, in addition to Berberine and Red&#xD;
      Rice, contains Morus Alba's extract. The study will analyze the impact of 16 week treatment&#xD;
      with one of the combinations, according to a randomized scheme, on metabolic parameters in&#xD;
      dyslipidemic subjects that do not require or not tolerate a statin therapy. In particular, it&#xD;
      will assess the ability of the two combinations to reduce the levels of total and LDL&#xD;
      cholesterol, HbA1C, glicaemia and insulin and increase those of HDL cholesterol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The experimental design involves the construction of a multi-center, controlled, randomized,&#xD;
      single-blind, versus Armolipid Plus®.&#xD;
&#xD;
      Patients with mild hypercholesterolemia, of both sexes and aged between 18 and 75 years, will&#xD;
      be recruited, from the beginning of the study and for the next 2 weeks, from 30 Cv&#xD;
      specialists and/or GPs (25 patients each).&#xD;
&#xD;
      The subjects will be enrolled in the 50/50% male/female ratio ± 10% comparable for age, in&#xD;
      order to obtain a proper comparison between groups with similar demographic characteristics&#xD;
      or not statistically different.&#xD;
&#xD;
      The subjects, selected on the basis of inclusion and exclusion criteria, will be divided into&#xD;
      two groups, subjected to centralized randomization at the &quot;Diagnosis and Treatment of&#xD;
      hypertension Center&quot; to receive one of two different treatments, a tablet/day of the new&#xD;
      nutraceutical LopiGLIK® (Akademy Pharma) containing Morus Alba, immediately after a meal, vs.&#xD;
      a tablet/day of Armolipid Plus, always immediately after the meal. During the first two weeks&#xD;
      both groups will follow the prescribed diet and assume the placebo. At the end, blood tests&#xD;
      (traditional metabolic parameters, blood glucose, HbA1C, fasting insulin, transaminase&#xD;
      levels, CPK) and the endothelial function will be assesed. During the next 16 weeks a group&#xD;
      will assume LopiGLIK® (Akademy Pharma) containing Morus Alba, the other will assume Armolipid&#xD;
      Plus and everyone will continue to follow the prescribed diet. At the end of this period&#xD;
      blood tests will be repeated. Tablets of Armolipid Plus, LopiGLIK® and placebo will be&#xD;
      provided by Akademy Pharma free of charge&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">December 1, 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of LDL-Cholesterol levels</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increasing of HDL-Cholesterol levels</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of HbA1c levels</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of fastin insuline levels</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Cardiovascular Risk Factors</condition>
  <arm_group>
    <arm_group_label>LopiGLIK®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>first two weeks: Placebo + prescribed Diet then 16 weeks LopiGLIK® a tablet/day after a meal + Diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Armolipid Plus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>first two weeks: Placebo + prescribed Diet then 16 weeks Armolipid Plus a tablet/day after a meal + Diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Armolipid Plus</arm_group_label>
    <arm_group_label>LopiGLIK®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prescribed Diet</intervention_name>
    <arm_group_label>Armolipid Plus</arm_group_label>
    <arm_group_label>LopiGLIK®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>LopiGLIK®</intervention_name>
    <arm_group_label>LopiGLIK®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Armolipid Plus</intervention_name>
    <arm_group_label>Armolipid Plus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Total Cholesterol&lt;300 mg/dL&#xD;
&#xD;
          -  Total Cholesterol&gt;200 mg/dL&#xD;
&#xD;
          -  Cardiovascular Risk&lt;20%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Documented intolerance to one or more 'components LOPIGLIK / Armolipid PLUS&#xD;
&#xD;
          -  Previous cardiovascular events&#xD;
&#xD;
          -  Familiar severe dyslipidemia&#xD;
&#xD;
          -  Familiar high cardiovascular risk Hepatic or muscular disorders Subjects receiving&#xD;
             lipid-lowering drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Trimarco, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>FEDERICO II UNIVERSITY - NAPLES</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federico II University</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Trimarco V, Izzo R, Stabile E, Rozza F, Santoro M, Manzi MV, Serino F, Schiattarella GG, Esposito G, Trimarco B. Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial. High Blood Press Cardiovasc Prev. 2015 Jun;22(2):149-54. doi: 10.1007/s40292-015-0087-2. Epub 2015 Apr 14.</citation>
    <PMID>25870124</PMID>
  </results_reference>
  <results_reference>
    <citation>Carrizzo A, Ambrosio M, Damato A, Madonna M, Storto M, Capocci L, Campiglia P, Sommella E, Trimarco V, Rozza F, Izzo R, Puca AA, Vecchione C. Morus alba extract modulates blood pressure homeostasis through eNOS signaling. Mol Nutr Food Res. 2016 Oct;60(10):2304-2311. doi: 10.1002/mnfr.201600233. Epub 2016 Jun 27.</citation>
    <PMID>27234065</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 8, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2016</study_first_posted>
  <last_update_submitted>July 29, 2019</last_update_submitted>
  <last_update_submitted_qc>July 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Bruno Trimarco</investigator_full_name>
    <investigator_title>PROF OF CARDIOLOGY</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data available to principal investigator</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

